Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 7/20 | 0.68 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.68 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.52 |
| ▸ | HTR3B | O95264 | 2/20 | 0.52 |
| ▸ | HTR3A | P46098 | 2/20 | 0.52 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.52 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | HTR1D | P28221 | 1/20 | 0.51 |
| ▸ | HTR1B | P28222 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6205989 | 0.95 | NCF1 (0.62) | NCF1ADRB2ADRB1POLBHTR3E | |
| SCHEMBL2881245 | 0.89 | NCF1 (0.60) | NCF1ADRB2ADRB1POLBHTR3E | |
| SCHEMBL8237908 | 0.86 | NCF1 (0.72) | NCF1ADRB2ADRB1HTR3AHTR2C | |
| SCHEMBL5637415 | 0.84 | NCF1 (0.70) | NCF1ADRB2ADRB1HTR3EHTR3B | |
| SCHEMBL14515746 | 0.84 | NCF1 (0.60) | NCF1ADRB2ADRB1HTR3EHTR3B | |
| SCHEMBL30058969 | 0.81 | NCF1 (1.00) | NCF1ADRB2ADRB1HTR6LMNA | |
| SCHEMBL899675 | 0.81 | NCF1 (1.00) | NCF1ADRB2ADRB1HTR6LMNA | |
| SCHEMBL900102 | 0.80 | NCF1 (0.65) | NCF1ADRB2ADRB1HTR3EHTR3B | |
| SCHEMBL4171486 | 0.80 | NCF1 (0.63) | NCF1ADRB2ADRB1HTR3AHTR2C | |
| SCHEMBL431110 | 0.78 | NCF1 (0.60) | NCF1ADRB2ADRB1HTR2CHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010081851-A1 | PIPERIDIN-4-YLPIPERAZINE COMPOUNDS FOR THE TREATMENT OF HCV INFECTION | GENOSCIENCE PHARMA (FR) | 2010-07-22 | — | — | WO | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-7220856-B2 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| CN-1678586-A | Substituted quinoline CCR5 receptor antagonists | SCHERING AG (DE) | 2005-10-05 | — | — | CN | disclosed |
| EP-1534681-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
| WO-2004002960-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | NCF1 2805/4885ADRB2 635/4885ADRB1 1030/4885 |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | NCF1 1080/4885ADRB2 58/4885ADRB1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.